BioPharmSignal logoBioPharmSignal

Biotech News

Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)

Ascendis Pharma (ASND)Ascendis PharmaPartnership

COPENHAGEN, Denmark, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has entered into a binding term sheet for a global settlement and license agreement with BioMarin Pharmaceutical Inc. (“BioMarin”) related to the sale of YUVIWEL ® and navepegritide-related

Related news

ASNDAscendis Pharma2026-04-06 20:01 EST

Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States

ASNDAscendis Pharma2026-02-27 22:57 EST

FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older

View all latest news

Ascendis Pharma

TransCon Technology Ascendis Pharma applies its TransCon prodrug platform to create long-acting therapies that release an unmodified parent drug over time. Its portfolio spans endocrinology, rare growth disorders and oncology. Commercial Endocrinology Portfolio YORVIPATH is a parathyroid-hormone replacement therapy for chronic...

Recent company news

ASNDAscendis Pharma2026-10-16 12:29 EST

Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children

ASNDAscendis Pharma2026-10-06 13:15 EST

Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026

ASNDAscendis Pharma2026-09-14 22:00 EST

Ascendis Announces Planned $400 Million Share Repurchase Program

ASNDAscendis Pharma2026-09-14 22:00 EST

Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases

ASNDAscendis Pharma2026-09-14 22:00 EST

Ascendis Announces Planned $400 Million Share Repurchase Program

Stock data

Close
242.99 USD
Market cap
13.38B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States